Drug Trial Radar · NCT05676853
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Apr 4, 2023
Primary completion
Apr 27, 2023
Study completion Apr 27, 2023
Sponsor
- Lead sponsor
- Aeglea BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.
Conditions
- Arginase I Deficiency
- Hyperargininemia
Interventions
PegzilarginaseDrug
Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse eventsTime frame: Baseline through week 54
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.